Allogene Therapeutics, Inc. 8-K

What Happened
Allogene Therapeutics (filed 8-K on April 13, 2026) announced interim futility results from its randomized Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel) used as MRD-guided first-line consolidation in large B‑cell lymphoma (LBCL). The analysis is based on the first 24 randomized patients (12 cema-cel, 12 observation); primary endpoint (event-free survival, EFS) and other key survival endpoints remain blinded.

Key Details

• MRD clearance at the protocol cutoff: 58.3% (7/12) in the cema-cel arm vs. 16.7% (2/12) in observation — an absolute difference of 41.6 percentage points.
• Early ctDNA change (Day 45): median 97.7% decrease from baseline in the cema-cel arm vs. a 26.6% median increase in observation.
• Safety in these 24 patients: no CRS, ICANS, or GvHD reported; infections 16.7% in each arm (all low grade); "other neurologic events" reported in 50.0% of cema-cel patients vs. 8.3% in observation (all low grade). Ten of 12 cema-cel patients were managed entirely outpatient post-infusion.
• Trial scope and timing: enrolling across >60 sites, ~220 planned patients; study powered to detect a 50% reduction in EFS events; anticipated interim EFS analysis mid-2027 and primary EFS analysis mid-2028 (could support a BLA if positive).
• Data caveat: results come from a small interim cohort; baseline imbalance favored more aggressive disease in the cema-cel arm (e.g., 100% stage III–IV vs. 83.3%; 50% double‑hit vs. 16.7%).

Why It Matters
For investors, these interim results show cema-cel producing substantially higher MRD clearance and fast ctDNA reductions versus observation, which—if sustained in larger cohorts and linked to EFS/PFS improvements—could support a regulatory filing and a new allogeneic CAR‑T use in earlier-stage LBCL. However, the company stresses (and the filing cautions) that these are early, small-sample data and the definitive impact on survival endpoints remains blinded and subject to future analyses and regulatory review.